Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Schönborn – page 11

1 165 clinical trials in Bad Schönborn, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Schönborn at a glance
1 165
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 165 trials in Bad Schönborn

Open in trial search

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Schönborn

What the registry says about research in the country

01 Chronic Sinusitis Research

Innovative clinical trials exploring LYR-210 depot therapy for patients with chronic rhinosinusitis who haven't responded to conventional treatments. This research focuses on improving the three cardinal symptoms of CRS in patients without nasal polyps.

  • Chronic Rhinosinusitis Management
  • Non-Polyp CRS Treatment
  • Alternative Therapeutic Approaches

Research aims to provide new options for patients who have exhausted traditional medical management strategies.

02 House Dust Mite Allergy Studies

Comprehensive evaluation of subcutaneous immunotherapy for moderate to severe allergic rhinitis and rhinoconjunctivitis. The research examines a specialized treatment protocol using PURETHAL Mites Mixture for patients with or without concurrent asthma.

  • Allergic Rhinitis Treatment
  • Immunotherapy Efficacy
  • Combined Symptom Management

This study measures treatment effectiveness through the Total Combined Rhinitis Score over a one-year period.

03 Seasonal Allergy Research

Investigation of PQ Birch therapy for seasonal allergic conditions, specifically targeting birch pollen-induced rhinitis and rhinoconjunctivitis. The research evaluates both safety and efficacy parameters.

  • Seasonal Rhinitis Treatment
  • Birch Pollen Allergies
  • Therapeutic Innovation

The study focuses on developing targeted solutions for seasonal allergy sufferers during birch pollen season.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.